Kadcyla

Trastuzumab emtansine, the active ingredient in Kadcyla, is an antibody‑drug conjugate presented as an injectable solution for intravenous infusion use. It treats HER2‑positive metastatic breast cancer and HER2‑positive early‑stage breast cancer in adult patients and is classified as an antineoplastic agent.\n\nGNH India supplies Kadcyla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Kadcyla is used in the HER2‑targeted treatment pathway for breast cancer.\n\n- HER2‑positive metastatic breast cancer: improves overall survival and delays disease progression.\n- HER2‑positive early‑stage breast cancer (adjuvant setting): reduces risk of recurrence after surgery.\n- HER2‑positive locally advanced breast cancer: provides tumor shrinkage to enable surgery.

Kadcyla may cause a range of adverse reactions, which are categorized by frequency.\n\nCommon Side Effects:\n- Fatigue: feeling of tiredness or lack of energy.\n- Nausea: sensation of needing to vomit.\n- Thrombocytopenia: reduced platelet count leading to easy bruising.\n- Elevated liver enzymes: increased ALT/AST indicating liver stress.\n\nSerious or Rare Side Effects:\n- Cardiac dysfunction: decreased heart ejection fraction or heart failure.\n- Interstitial lung disease: inflammation of lung tissue causing cough and breathing difficulty.\n- Severe infusion‑related reactions: anaphylaxis or severe allergic response during administration.

When using Kadcyla, clinicians should observe several precautionary measures to ensure patient safety.\n\n- Cardiac monitoring: assess baseline and periodic left ventricular ejection fraction.\n- Hepatic function: evaluate liver enzymes before each cycle.\n- Hematologic assessment: monitor platelet counts and complete blood count regularly.\n- Pregnancy and lactation: avoid use in pregnant or breastfeeding women unless benefits outweigh risks.\n- Concomitant therapies: review other anticancer agents for overlapping toxicities.\n- Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kadcyla can interact with other medicines, affecting its safety or efficacy.\n\nMajor Interactions (Avoid):\n- Anthracyclines: combined use may increase cardiotoxicity risk.\n- HER2‑targeted tyrosine kinase inhibitors: overlapping cardiac effects.\n\nModerate Interactions (Monitor Closely):\n- CYP3A4 inhibitors/inducers: may alter DM1 metabolism.\n- Anticoagulants: increased bleeding risk with thrombocytopenia.\n- Live vaccines: immunosuppression may reduce vaccine efficacy.